Prediction for prognosis of resected pT1a-lbN0M0 adenocarcinoma based on tumor size and histological status: Relationship of TNM and IASLC/ATS/ERS classifications

被引:38
作者
Ito, Masaoki [1 ]
Miyata, Yoshihiro [1 ]
Kushitani, Kei [2 ]
Yoshiya, Tomoharu [1 ]
Mimae, Takahiro [1 ]
Ibuki, Yuta [1 ]
Misumi, Keizo [1 ]
Takeshima, Yukio [2 ]
Okada, Morihito [1 ]
机构
[1] Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Surg Oncol, Minami Ku, Hiroshima 7348551, Japan
[2] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Pathol, Minami Ku, Hiroshima 7348551, Japan
关键词
Lung cancer; Adenocarcinoma; Tumor staging; In situ; Invasive; Prognosis; Recurrence; STAGING SYSTEM REVISIONS; FORTHCOMING 7TH EDITION; IASLC LUNG-CANCER; INTERNATIONAL-ASSOCIATION; ADJUVANT CHEMOTHERAPY; DISEASE RECURRENCE; VALIDATION; PROPOSALS; SURVIVAL; TEGAFUR;
D O I
10.1016/j.lungcan.2014.05.014
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Objectives: This study aimed to estimate the relationship between 7th TNM classification and IASLC/ATS/ERS classification with regard to tumor size and pathological status and to determine the utility of these classifications for predicting prognosis in resected node-negative adenocarcinoma with tumor size <= 2.0 cm and >2.0-3.0 cm. Materials and methods: We reviewed 321 pN0M0 lung adenocarcinoma cases resected at Hiroshima University Hospital from January 1991 to December 2010. Histological differences between T1a and T1b based on the IASLC/ATS/ERS classification were estimated and followed by evaluation of overall survival (OS) and recurrence-free interval (RFI) based on differences in tumor size and histological features. Results: We found 188 cases of pT1a-1bN0M0 (135 T1a, 53 T1b). Pathological T1a tumors included significantly more adenocarcinoma in situ (AIS) cases and minimally invasive adenocarcinoma (MIA) cases than T1b tumors (60.7% vs 18.8%, respectively; p<0.0001), while more invasive adenocarcinoma cases were included in pT1b. By considering the two classifications simultaneously, the 5-year OS rates of T1a AIS/MIA, T1b AIS/MIA, T1a invasive adenocarcinoma, and T1b invasive adenocarcinoma were 97.5%, 87.5%, 95.8%, and 86.8%, respectively. The 5-year RFIs of T1a AIS/MIA, T1b AIS/MIA, T1a invasive adenocarcinoma, and T1b invasive adenocarcinoma were 100%, 100%, 91.3%, and 72.5%, respectively. T1a AIS/MIA and T1b AIS/MIA could be separated as good prognostic cases with a 100% RFI. Multivariate analysis indicated that only T1b invasive adenocarcinoma was an independent factor for predicting recurrence (p = 0.001). Conclusion: Compared to a single classification, combining TNM and IASLC/ATS/ERS classifications could provide more detail information concerning disease recurrence. AIS and MIA should be handled equally, regardless of tumor size, because their non-/less invasive status is more useful for predicting prognosis than their tumor size classification. In contrast, the T descriptors based on TNM classification are important for predicting prognosis in invasive adenocarcinoma. (C) 2014 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:270 / 275
页数:6
相关论文
共 23 条
[1]
[Anonymous], CHRISTIAN WITTEKIND
[2]
Borezuk AC, 2009, AM J SURG PATHOL, V33, P462, DOI 10.1097/PAS.0b013e318190157c
[3]
Validation of the lung cancer staging system revisions using a large prospective clinical trial database (ACOSOG Z0030) [J].
Fibla, Juan J. ;
Cassivi, Stephen D. ;
Decker, Paul A. ;
Allen, Mark S. ;
Darling, Gail E. ;
Landreneau, Rodney J. ;
McKenna, Robert J. ;
Putnam, Joe B. .
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2013, 43 (05) :911-914
[4]
Goldstaw P, 2009, STAGING MANUAL THORA, P39
[5]
The IASLC lung cancer staging project: Proposals for the revision of he TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours [J].
Goldstraw, Peter ;
Crowley, John ;
Chansky, Kari ;
Giroux, Dorothy J. ;
Groome, Patti A. ;
Rami-Porta, Ramon ;
Postmus, Pieter E. ;
Rusch, Valerie ;
Sobin, Leslie .
JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) :706-714
[6]
Effect of Postoperative Adjuvant Chemotherapy with Tegafur-Uracil on Survival in Patients with Stage IA Non-small Cell Lung Cancer An Exploratory Analysis from a Meta-Analysis of Six Randomized Controlled Trials [J].
Hamada, Chikuma ;
Tsuboi, Masahiro ;
Ohta, Mitsuo ;
Fujimura, Shigefumi ;
Kodama, Ken ;
Imaizumi, Munehisa ;
Wada, Hiromi .
JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (12) :1511-1516
[7]
Evaluation of the new TNM staging system proposed by the International Association for the Study of Lung Cancer at a single institution [J].
Kameyama, Kotaro ;
Takahashi, Mamoru ;
Ohata, Keiji ;
Igai, Hitoshi ;
Yamashina, Akihiko ;
Matsuoka, Tomoaki ;
Nakagawa, Tatsuo ;
Okumura, Norihito .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2009, 137 (05) :1180-1184
[8]
Clinicopathological characteristics of subcentimeter adenocarcinomas of the lung [J].
Kato, Fumiaki ;
Hamasaki, Makoto ;
Miyake, Yoshihiro ;
Iwasaki, Akinori ;
Iwasaki, Hiroshi ;
Nabeshima, Kazuki .
LUNG CANCER, 2012, 77 (03) :495-500
[9]
A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung [J].
Kato, H ;
Ichinose, Y ;
Ohta, M ;
Hata, E ;
Tsubota, N ;
Tada, H ;
Watanabe, Y ;
Wada, H ;
Tsuboi, M ;
Hamajima, N ;
Ohta, M .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (17) :1713-1721
[10]
NOGUCHI M, 1995, CANCER-AM CANCER SOC, V75, P2844, DOI 10.1002/1097-0142(19950615)75:12<2844::AID-CNCR2820751209>3.0.CO